Abstract. Antisense noncoding RNA in the INK4 locus (ANRIL) has been reported to be upregulated in various types of human cancer, and is also highly expressed in normal human tissue. The aim of the present study was to identify whether ANRIL may be a possible target for colorectal cancer (CRC) therapy. Reverse transcription-quantitative polymerase chain reaction was used to quantify the expression levels of the long noncoding RNA (lncRNA) ANRIL in 97 paired CRC and adjacent non-neoplastic tissue samples. In addition, the HT29 and RKO human CRC cell lines underwent ANRIL RNA interference, and knockdown efficiency was evaluated by western blotting. Cell viability, and migratory and invasive ability were subsequently assessed. The CRC tissues were revealed to express higher levels of ANRIL lncRNA compared with the adjacent non-neoplastic tissues (P<0.05). Furthermore, high ANRIL expression was significantly associated with reduced survival rate (P<0.05). ANRIL gene expression was successfully silenced in human CRC cells. ANRIL knockdown decreased proliferation, inhibited migration and invasion, and reduced the colony-forming ability of the cells. These data indicated that the lncRNA ANRIL is upregulated in CRC tissues, and is associated with CRC cell pathogenesis. Furthermore, the underlying mechanisms of these effects may be exploited for therapeutic benefit.
Introduction
Colorectal cancer (CRC) is currently the third most common malignancy worldwide (1, 2) , thus representing a significant health burden. Despite advances in treatment options and availability, minimal improvements have been made regarding the survival rate of patients with CRC. This lack of improvement may be due to the absence of early detection techniques and optimal predictions regarding disease outcome. Therefore, exploring the biomarkers associated with CRC, and increasing knowledge regarding the molecular mechanisms of CRC is required (3) .
Long noncoding RNAs (lncRNAs) are transcribed RNA molecules, >200 nt long, which are not translated into protein.
LncRNAs regulate gene expression at several levels including epigenetic, transcriptional and post-transcriptional levels. In addition, lncRNAs have been hypothesized to participate in physiological and pathological cell processes (4, 5) . Previous studies have reported on the role of lncRNAs in the regulation of various genes (6) (7) (8) (9) (10) . Their downstream effector genes are associated with transcriptional initiation (11) , protein structure (12) , and suppression (13, 14) . LncRNAs comprise a large family; however, the number of lncRNAs that have been well-studied with regards to their established function is small. Previous studies have reported that numerous lncRNAs are closely correlated with various types of malignancies, acting as oncogenes or tumor suppressors (15) (16) (17) (18) .
Research regarding the effects of lncRNAs on CRC is currently in the preliminary stage, and associated studies are rare (19) . In addition, despite the growing interest regarding lncRNA as a potential therapeutic target (20, 21) , the exact function of lncRNAs in CRC tumorigenesis remains unknown. The present study aimed to investigate the regulatory role of the lncRNA antisense noncoding RNA in the INK4 locus (ANRIL) in CRC patient outcome, and the effects of ANRIL knockdown on CRC cell proliferation, and migratory and invasive ability.
Materials and methods
Patient samples. A total of 97 patients, including 46 males and 51 females, with an average age of 66 years old, were recruited from Guizhou Provincial People's Hospital (Guizhou, China).
The patients were in the late clinical stages of CRC, and had undergone surgery between May 2010 and May 2013. Adjacent non-neoplastic tissue and primary CRC tumor tissue samples were collected from each of the patients. The Institutional Review Board Affiliated to Guiyang Medical University (Kaili, China) approved the protocol of the present study to be used for the patients at Guizhou Medical University, and informed consent was collected from each patient prior to surgery. Liquid nitrogen was used to promptly freeze the tissue samples following the surgical procedure. The patients were free of any other diseases, and had no prior experience of chemotherapy or radiotherapy. A minimum of two senior pathologists examined the CRC tissues, in order to confirm diagnosis of the disease. 
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HT29 and RKO cells were subsequently transfected with the reconstructed shRNA plasmids along with two helper plasmids (pVSVG-I and pCMVR8.92; Shanghai HollyBio) using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The recombinant virus was then cultured in DMEM for 72 h at 37˚C. Finally, 6x10 3 cells/well were incubated with the ANRIL shRNA-expressing lentivirus or negative control for 24 h at 37˚C.
Cell viability assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method was used to determine cell viability. Briefly, 1x10 4 shRNA-transfected cells were seeded in 96-well plates for 48 h at 37˚C, and 100 µl MTT (Sigma-Aldrich) was then added to each well. The plates were incubated for 4 h at 37˚C, until purple formazan crystals developed. Subsequently, each well was washed with 100 µl dimethyl sulfoxide and was air-dried at room temperature for 30 min. Cell viability was quantified by measuring the absorbance of the plate at A490 using a Universal Microplate Spectrophotometer (Thermo Fisher Scientific, Inc.).
Cell migration and invasion assays.
The migratory and invasive capabilities of the CRC cells were measured in a Transwell chamber system. In the upper chamber, a solution of 60 µl diluted extracellular matrix (ECM; Corning Life Science, Lowell, CA, USA) was added. For the migration assay, the same method was used; however the ECM membrane was not added to the upper chamber. The chamber was incubated at 37˚C for 4 h. Subsequently, 1x10
5 cells/well were seeded into the upper chamber in 100 µl DMEM containing 1% FBS. The lower chambers of the Transwell were filled with 500 µl DMEM containing 10% FBS. To allow for cell migration, the Transwell was incubated for 20 h at 37˚C in an atmosphere containing 5% CO 2 . Once incubation was complete a cotton swab was used to carefully remove the cells from the upper chamber. Cells at the bottom of the ECM gel-coated membrane were fixed and stained with paraformaldehyde and crystal violet. After dissolving the crystal violet in 200 µl glacial acetic acid the plate was incubated for 30 min at room temperature. The number of migrated and invaded cells on the bottom side of five randomly selected visual fields (x100 A B magnification) per well was counted using an inverted microscope (Nikon Eclipse TS100, Nikon, Tokyo, Japan).
Western blot analysis. Protein was prepared with a lysis buffer by adding protease and phosphatase inhibitors (Thermo Fisher Scientific, Inc.) followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis separation. Protein was then transferred to nitrocellulose membranes under semi-dry system conditions (Bio-Rad Laboratories, Hercules, CA, USA). Incubate membrane in 25 ml of blocking buffer for 1 h at room temperature and wash three times for 5 min each with 15 ml of 1X Tris-buffered saline with Tween-20 (TBST) (Santa Cruz Biotechnology Inc, Dallas, TX, USA). Next, the membranes were incubated with primary antibodies anti-p15/CDKN2B (cat. no. Sc-612) and mouse anti-β-actin (cat. no. sc-47778) at 4˚C overnight. Following two continuous washes for 5 min each with TBST, the membranes were then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (cat. no. sc-2004) and horseradish peroxidase-conjugated goat anti-mouse IgG (sc-2005) secondary antibody. All of the antibodies were purchased from the Santa Cruz Biotechnology, Inc. Protein expression was visualized with a gel imaging system (Bio-Rad Laboratories).
Cell colony formation. Untreated negative control (shControl) cells and cells with ANRIL silencing (shANRIL) were seeded into a 6-well plate with 100 cells per well and cultured for 72 h at 37˚C. After washing twice with phosphate-buffered saline (Sigma-Aldrich), cells were continually cultured for 7 days at 37˚C and the medium was refreshed every three days. Then the cells were fixed in methyl alcohol and stained by 10% Giemsa (Sigma-Aldrich). Only colonies with >50 cells were counted under an inverted microscope (Nikon Eclipse TS100).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
. RNA was extracted from homogenized cells and tissues. Total RNA was extracted using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and was stored at -80˚C until further use. RT-qPCR was performed with SYBR Premix Ex Taq II kit, according to the manufacturer's protocol (Takara Biotechnology Co., Ltd., Dalian, China). qPCR was conducted using SYBR green fluorescent dye and the ABI 7900 fast sequence detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.).
The following primers were used: ANRIL, forward Statistical analysis. SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used to statistically analyze the data. Numerical data are presented as the mean ± standard deviation. Statistical analysis was carried out using Student's t-test to evaluate the statistical differences between normal and gene knockdown cells. One-way analysis of variance followed by the post-hoc multiple comparisons least significant difference test were performed to compare the significant differences between three or more groups. The χ 2 test and Fisher's exact test was used to compare percentage distribution between the different groups. Each experiment was repeated at least twice or was performed in triplicate. The Kaplan-Meier method was used to draw a survival curve and evaluate the prognostic value of the ANRIL expression level in colorectal cancer. P<0.05 was considered to indicate a statistically significant difference.
Results

Correlation of patient clinical characteristics and ANRIL expression in tissue samples. The results of RT-qPCR
analysis demonstrated that the expression levels of ANRIL were increased in CRC tissues compared with in the adjacent normal tissues (Fig. 1A) . However, no significant association was detected between ANRIL expression and gender, age (Table I) . Relative ANRIL expression >1.5 (tumor/normal) was set as a criteria for high expression, and the 97 patients were divided into ANRIL-high (n=53) and ANRIL-low groups (n=44). Generation of a survival curve indicated that high expression levels of ANRIL are a significant predictor of a worse clinical outcome compared with low expression levels (P<0.05; Fig. 1B) .
Evaluation of knockdown efficiency of ANRIL shRNA in CRC cells. Initially ANRIL expression was detected in four selected CRC cell lines: SW480, HCT116, HT29 and RKO, and in the HCoEpiC human colonic epithelial cell line (Control). The results indicated that ANRIL expression levels were highest in the HT29 and RKO cells, compared with the other two CRC cell lines and the control ( Fig. 2A) . Therefore, HT29 and RKO cells were used in subsequent experiments. Analysis of knockdown efficiency demonstrated that the constructed lentivirus inhibited ANRIL expression. Since ANRIL, also known as CDKN2B-AS, is a long non-coding RNA located within p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster and closely associated with p15/CDKN2B, p16/CDKN2A and p14/ARF expression. p15/CDKN2B protein (Sc-612, Santa cruz, USA) was used in the western blot analysis to confirm the ANRIL knockdown efficiency in HT-29 and RKO cells. p15/CDKN2B protein expression was inhibited in the majority of cells 72 h post-lentiviral infection (Fig. 2B ). In addition, ANRIL mRNA expression was significantly decreased in the infected cells (P<0.05; Fig. 2C ).
Lentivirus-mediated ANRIL shRNA significantly inhibits growth of CRC cells. Cell proliferation was evaluated using the MTT method. As shown in Fig. 3A , the growth rate of knockdown cells was significantly impaired compared with the shControl group (P<0.05). A colony formation assay was also performed. A reduced number of cell colonies was observed following ANRIL knockdown. Compared with the shControl cells the ANRIL shRNA-treated cells exhibited decreased colony-forming ability (Fig. 3B) .
ANRIL knockdown prevents cell invasion and migration.
Compared with the shControl group, there was an evident decrease in the number of ANRIL shRNA-treated cells that crossed the membrane (Fig. 4) . Cells that invaded through the membrane were stained with crystal violet. In addition, Compared with the shControl group, the invasive capability of cells in the ANRIL shRNA group was decreased.
Discussion
The role of lncRNAs in carcinogenesis has garnered a lot of attention, and previous studies have examined the relationship between lncRNAs and tumor growth, epithelial-mesenchymal transition and metastasis (14, 16, 23) . However, there seems to be a lack of evidence demonstrating the relationship between CRC and lncRNAs. Previous studies have revealed the vital role lncRNAs can have in CRC; the lncRNAs HOX transcript antisense RNA, metastasis associated lung adenocarcinoma transcript 1, H19 and colon cancer associated transcript 1 have been shown to enhance the progression of CRC and may be used as biomarkers for CRC prognosis (24, 25) . The results of the present study demonstrated that higher levels of the lncRNA ANRIL are present in CRC tissue compared with adjacent non-neoplastic tissues.
The relatively high expression of ANRIL was significantly associated with decreased survival rate. In addition, ANRIL gene expression was successfully silenced in human CRC cells. ANRIL knockdown decreased proliferation, inhibited migration and invasion, and reduced the colony-forming ability of CRC cells.
The ANRIL gene (NR_003529), also known as CDKN2B antisense RNA 1, is comprised of 19 exons and has a span of 126.3 kb. The ANRIL gene is contained within the antisense gene cluster p15/CDKN2B-p16/CDKN2A-p14/ADP-ribosylation factor 1 (ARF), which produces a 3,834-bp mRNA transcript. The two exons of p15/CDKN2B are overlapped by ANRIL intron 1. The ANRIL gene has a 5' end on its first exon, which is located ~300 bp upstream of the p14/ARF gene transcription start site. Both genes, ANRIL and p14/ARF, may share corresponding transcription due to their clustered expression in normal human tissues, as well as within various tumors (26) . Novel insights into the transcriptional regulation of ANRIL and p14/ARF have suggested it is due to the mapping of CCCTC-binding factor (CTCF)-binding sites on the CpG island, which overlap the ANRIL-p14/ARF promoters (27) . The CTCF insulator protein is a highly conserved zinc finger protein, which is a critical factor essential for transcription of the p15/CDKN2B-p16/CDKN2A-p14/ARF locus due to its chromatin barrier activity (28) . In neurofibromatosis type 1, ANRIL has a role in the development of plexiform neurofibromas (29) . In addition, ANRIL helps to suppress and downregulate the tumor gene p15 (INK4B) through the process of attaching itself and recruiting the suppressor of zester 12 homolog (Drosophila) (12) , which is a component of the polycomb repressive complex 2 (30) . The ATM-E2F transcription factor 1 signaling pathway is activated when DNA damage occurs via ANRIL upregulation (31, 32) . In the present study, RT-qPCR was conducted to measure the expression levels of ANRIL in clinical tissues and cell lines. A total of 46.3% of CRC tissues exhibited ANRIL overexpression, predominantly in progressed tumor tissues that are large in size with lymph node metastasis. These results indicated that ANRIL may be a primary participant in the advancement of CRC, and may not be present during initial onset, suggesting that ANRIL may be a likely biomarker for late stage CRC with metastasis. Inhibition of ANRIL suppressed tumor growth in vitro, and inhibited cell migration and invasion, further supporting the cancerous role of ANRIL in CRC. In addition, these results suggested that elimination of ANRIL may inhibit CRC cell proliferation, and block the migratory and invasive ability of the cells.
Qiu et al (33) demonstrated that small interfering RNA-mediated ANRIL silencing in ovarian cancer cells suppressed migration and invasion of these cells, thus suggesting that the lncRNA ANRIL has a critical role in the invasion or metastasis of serous ovarian cancer.
Hua et al (34) performed in vitro assays, which revealed that decreased expression of ANRIL may suppress the proliferation, migration and invasion of hepatocellular carcinoma cells. Furthermore, Huang et al (35) reported that reduced ANRIL expression in vitro and in vivo may reduce cell growth and invasion, and induce cell apoptosis. These findings, alongside those of the present study, illustrate how ANRIL is a major player in CRC. In conclusion, further research is still required in order to examine the underlying mechanisms and functions of ANRIL in CRC, as well as the possibility of using ANRIL as a therapeutic target for CRC.
